Panbela Therapeutics Inc.

IN THE PRESS

Business

Panbela to Host Fourth Quarter and Year End 2022 Earnings Conference Call on March 16, 2023

March 8, 2023

·

6 min read

BioMidwest

Panbela Announces First Patient Enrolled in South Korea for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

March 7, 2023

·

6 min read

BioMidwest

Panbela Announces Closing of Approximately $15 Million Public Offering, and Regains Compliance with Nasdaq Listing Standards

February 13, 2023

·

8 min read

Deals

Panbela Announces Pricing of Approximately $15 Million Public Offering

January 26, 2023

·

8 min read

BioMidwest

Panbela Announces Adoption of Commission Implementing Decision from the EMA for the Orphan Designation of Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

January 19, 2023

·

7 min read

BioMidwest

Panbela Announces 1-for-40 Reverse Stock Split effective January 13, 2023

January 12, 2023

·

5 min read

Drug Development

Panbela Starts Phase II Trial of CPP-1X-T for Recent Onset Type I Diabetes, in Collaboration with Indiana University School of Medicine and JDRF

January 11, 2023

·

7 min read

BioMidwest

Panbela Receives Positive EMA Opinion on Orphan Designation for Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

December 14, 2022

·

7 min read

BioMidwest

Panbela Announces First Patients Enrolled in Europe for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

November 28, 2022

·

7 min read

Business

Panbela Provides Business Update and Reports Q3 2022 Financial Results

November 10, 2022

·

13 min read

JOBS